Drug intelligence / Profile preview

Quemicetina con Hidrocortisona

Development stage
Unknown
Lead developer
Laboratorios Lafedar
Modality
Small Molecules
Administration
Ophthalmic, Topical
01

Overview

Quemicetina con Hidrocortisona is a combination pharmaceutical product developed and manufactured by Lafedar (Laboratorios Federales Argentinos). It contains chloramphenicol, a broad-spectrum antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, and hydrocortisone caprylate, a corticosteroid that provides anti-inflammatory and immunosuppressive effects. This combination is used for treating ophthalmic and dermatological conditions where both bacterial infection and inflammation are present. It is marketed in Argentina as a generic combination drug and is available in various solution volumes, including 5ml, 500ml, and 1000ml containers.

Brand names
Quemicetina con HidrocortisonaChemicetin with Hydrocortisone
Other names
chloramphenicol + hydrocortisone caprylateChemicetin + hydrocortisone
02

Targets

GR (Glucocorticoid receptor)Bacterial 50S ribosomal subunit

Beyond the preview

Go deeper on Quemicetina con Hidrocortisona.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Quemicetina con Hidrocortisona.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call